KBI Biopharma, Inc. Announces Collaboration with Infinimmune Inc. to Support Antibody Manufacturing
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Infinimmune, Inc., a biotechnology company pioneering human-first antibody discovery and design, announced a collaboration to advance manufacturing of Infinimmune’s lead human monoclonal antibody (“IFX-101”) program.
The first antibody in Infinimmune’s therapeutic drug development pipeline, IFX-101, targets atopic dermatitis and is designed to deliver superior efficacy with extended dosing intervals for improved patient quality of life. By sourcing antibodies directly from the human immune system, Infinimmune taps into a naturally optimized, safe, and effective therapeutic reservoir, rather than engineering from scratch. Infinimmune’s GLIMPSE™ platform – a protein language model trained solely on native human antibody sequences – learns from millions of successful immune responses to engineer superior antibodies that harness evolution-proven strategies with enhanced biologic properties. This combination creates a potent platform that’s uniquely differentiated in the biologics field.
“We are pleased to partner with KBI Biopharma to advance our lead antibody program,” said Wyatt McDonnell, Ph.D., CEO and Co-Founder, Infinimmune. “By combining our Anthrobody® and GLIMPSE™ platforms together with KBI’s development and manufacturing expertise, we’re positioned to rapidly advance toward clinical trials. Our human-first approach enables us to deliver what patients really need – more effective treatments with greater convenience. This collaboration is an important step in our mission to bring transformative, human-first antibodies to patients in need."
“KBI is proud to support Infinimmune in its effort to transform biologics and deliver safer, more effective antibody therapeutics,” said Katie Edgar, Chief Business Officer of KBI Biopharma. “Our strategic partnership will be highly synergistic in biologics development, by combining Infinimmune’s cutting-edge antibody discovery with KBI’s deep expertise in development and manufacturing capabilities.”
The IFX-101 program is progressing at KBI’s Cell Line Development Center of Excellence in Geneva, Switzerland, using KBI’s advanced monoclonal antibody development and manufacturing platform, SUREmAb™, powered by Selexis.
About Infinimmune
Infinimmune is a biotechnology company pioneering a novel approach to antibody drug discovery and development. Founded by a world-class, multidisciplinary team of scientists and technologists, Infinimmune is reinventing antibody discovery with an end-to-end platform to deliver antibody drugs derived directly from the human immune system. These truly human antibodies are designed to drug new and existing targets with improved safety and efficacy. Infinimmune is building its own pipeline of drug candidates and partnering with pharmaceutical companies to advance their antibody programs, fill their pipelines, and reach new patients and new indications. To learn more, visit infinimmune.com and follow us on LinkedIn and @infinimmune.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. With each of its 500+ customer partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 170 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian and microbial programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global customers with six locations in Europe and the USA. More information is available at www.kbibiopharma.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250908013845/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Red Sea Global Announces the Opening of AMAALA: The World’s New Coastal Lifestyle Destination11.11.2025 16:30:00 CET | Press release
With spectacular resorts, an exclusive yacht club, and world-leading marine life institute, RSG’s latest destination sets new global standards for holistic wellness and environmental stewardship Red Sea Global (RSG), the real estate developer and pioneer of regenerative tourism, announced the highly anticipated opening of AMAALA Triple Bay during the inaugural TOURISE Summit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111682859/en/ Sea meets land: The world class AMAALA Triple Bay Marina Yacht Club on the Saudi Red Sea coastline Nestled across three naturally occurring bays on Saudi Arabia’s rugged north-western coast where the Hijaz Mountains meet the Red Sea, the ultra-luxury, wellness destination is set to open in the coming months. “Deriving from the Arabic word for hope, AMAALA offers a new coastal lifestyle rooted in wellness right here in Saudi Arabia. Guests and residents are invited to discover and honor what
Xsolla and Airbridge Partner to Deliver Unified Mobile and Web Performance Insights for Game Developers11.11.2025 15:36:00 CET | Press release
A New S2S Integration Connects Mobile and Web Data, Empowering Developers with a Unified View of Player Value and Marketing Performance Xsolla, a global commerce company helping developers launch, grow, and monetize their games, today announced a new mobile-focused Server-to-Server (S2S) integration with Airbridge, a leading unified measurement platform for mobile marketers. This strategic partnership empowers mobile game developers with precise, cross-platform performance tracking by bridging the gap between mobile marketing efforts and purchases made through the Xsolla Web Shop. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111170674/en/ (Graphic: Xsolla) As more developers turn to Web Shops to drive direct-to-consumer monetization beyond traditional app stores, understanding the full value of those off-platform transactions has become increasingly critical. With Xsolla’s new S2S integration, powered by Airbridge, deve
ThreatDown Launches Nexus Partner Program, Strengthening its Channel-First Commitment11.11.2025 15:02:00 CET | Press release
New program marks a strategic investment, putting partners at the center of ThreatDown’s growth strategy ThreatDown, the corporate business unit of Malwarebytes, today announced the launch of the Nexus Partner Program, a comprehensive initiative that puts partners at the center by strengthening collaboration and creating new growth opportunities for its global network of partners. The program aligns incentives, simplifies enablement, and strengthens collaboration to ensure every reseller has the resources and support needed to deliver smarter, stronger security outcomes for customers. “At ThreatDown, being channel-first means putting our partners at the center of everything we do,” says Kendra Krause, General Manager of ThreatDown. “The Nexus Partner Program reflects that belief – the program is built to equip partners with the tools they need to succeed in a rapidly evolving cybersecurity market. When our partners win, we win.” Available globally, the program offers competitive discou
Blue Matter Enhances Twine™ Platform Capabilities in Response to Growing Demand11.11.2025 15:01:00 CET | Press release
Blue Matter today announced the expansion of its Twine™ data platform’s capabilities in response to accelerating demand from biopharma companies. Enhancements include thoughtful use of artificial intelligence (AI) for advanced analytics and narratives, expanded data source integrations, master data management, and broader deployment across oncology and specialty therapeutic areas. Twine™ is Blue Matter's purpose-built customer intelligence platform for healthcare and life sciences companies. It transforms complex data from disparate sources including specialty pharmacy networks, hub services, claims databases, and other third party data sources into actionable insights that drive commercial strategy and operational excellence. With generative AI at its core, Twine helps companies more effectively acquire, master, validate, and analyze data from internal and third-party sources. Persona-specific outputs enable faster, more informed decision-making. According to Deepak Gopinath, Partner
Financial Sector Signals Rising Investment in Identity Verification11.11.2025 15:00:00 CET | Press release
Banks, fintechs, and crypto platforms are ramping up investment in fraud prevention and identity verification (IDV), positioning it as the next layer of cyber defense. According to Regula’s global survey, The Future of Identity Verification: 5 Threats and 5 Opportunities, banks are leading this trend: the share of institutions intending to increase IDV budgets by more than 50% is nearly tripling—from 4.4% to 15% in just two years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111008888/en/ Banks lead the IDV investment surge, but fintech, crypto, and aviation sectors are catching up fast, with roughly one in six companies planning to expand IDV budgets by more than 50%. Even healthcare is joining the trend, signaling how essential verification has become beyond finance. Moderate increases in identity verification budgets are becoming common across all financial services. Roughly a third of banks and crypto firms and a fi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom